Patient Preferences for Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGHY) in Adults with Primary Immunodeficiencies (PI): Phase 3 Study Results

被引：0
|
作者：
Ito, D. [1 ]
Ye, X. [2 ]
Xiong, Y. [1 ]
Li-McLeod, J. [1 ]
Schiff, R. [1 ]
Faivre, P. [3 ]
机构：
[1] Baxter HealthCare, Med Outcomes Res & Econ, Westlake Village, CA USA
[2] Baxter HealthCare, Med Outcomes Res & Econ, Deerfield, IL USA
[3] Baxter HealthCare, Hlth Econ & Market Access, Westlake Village, Switzerland
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
ESID-0294
引用
收藏
页码：S381 / S382
页数：2
相关论文
共 46 条
  • [1] Patient Preferences for Recombinant Human Hyaluronidase (rHuPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGHy) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results
    Ito, Diane
    Ye, Xiaolan
    Xiong, Yan
    Li-McLeod, Josephine
    Schiff, Richard
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 376 - 376
  • [2] Efficacy, Safety and Tolerability of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Phase 3 Study Results
    Stein, Mark R.
    Wasserman, Richard L.
    Melamed, Isaac
    Rubinstein, Arye
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    McCoy, Barbara
    Yel, Leman
    Schiff, Richard I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 380 - 381
  • [3] Long Term Safety, Efficacy, and Tolerability of Recombinant Human Hyaluronidase [RHUPH20] -Facilitated Subcutaneous Infusion of Immunoglobulin G (IGG) (HYQVIA; IGHY) in Adults with Primary Immunodeficiencies (PI)
    Wasserman, R. L.
    Stein, M.
    Melamed, I.
    Kobrynski, L.
    Grant, J. A.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Yel, L.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S310 - S311
  • [4] Safety and Pharmacokinetics (Pk) of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Extension Study of a Phase 3 Pivotal Trial
    Melamed, Isaac
    Wasserman, Richard L.
    Stein, Mark R.
    Rubinstein, Arye
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    Yel, Leman
    Schiff, Richard I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 379 - 379
  • [5] Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)
    Wasserman, Richard L.
    Stein, Mark R.
    Melamed, Isaac
    Kobrynski, Lisa J.
    Gupta, Sudhir
    Puck, Jennifer M.
    Rubinstein, Arye
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB96 - AB96
  • [6] LONG-TERM EFFICACY OF RECOMBINANT HUMAN HYALURONIDASE (RHUPH20)-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (IGHY; HYQVIA) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID): INFECTION RATES OVER THE COURSE OF TREATMENT
    Wasserman, R. L.
    Stein, M.
    Kobrynski, L.
    Gupta, S.
    Grant, J.
    Rubinstein, A.
    Engl, W.
    Mccoy, B.
    Leibl, H.
    Yel, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A102 - A102
  • [7] RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNO GLOBULIN G (IGG) (HYQVIA; IGHY) IN PATIENTS AGED ≥16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PI): LONG TERM SAFETY, EFFICACY, AND TOLERABILITY.
    Wasserman, R. L.
    Stein, M.
    Melamed, I.
    Kobrynski, L.
    Grant, J. A.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Yel, L.
    Schiff, R. I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A89 - A89
  • [8] LONG TERM SAFETY, EFFICACY AND TOLERABILITY OF RECOMBINANT HUMAN HYALURONIDASE [RHUPH20]-FACILITATED SUBCUTANEOUS (SC) INFUSION OF IMMUNOGLOBULIN G (IGG) (HYQVIA; IGHY) IN PEDIATRIC PATIENTS AGED <16 YEARS WITH PRIMARY IMMUNODEFICIENCIES (PID)
    Wasserman, Richard L.
    Melamed, Isaac
    Stein, Mark
    Kobrynski, Lisa
    Puck, Jennifer
    Gupta, Sudhir
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 (03) : 314 - 314
  • [9] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): SUBSET OF STUDY PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PI)
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 155 - 156
  • [10] Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs)
    Melamed, Isaac Reuven
    Wasserman, Richard L.
    Stein, Mark
    Rubinstein, Arye
    Puck, Jennifer M.
    Gupta, Sudhir
    Engl, Werner
    Leibl, Heinz
    Yel, Leman
    Schiff, Richard I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB180 - AB180
12345